Topic: Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS)

Aug 2022 | Assessment

Interventions of Interest: Relyvrio was removed from the market on April 4, 2024. Read ICER’s commentary on Amylyx’s decision to discontinue the drug here. Final Documents ICER’s Chief Medical Officer, David Rind, MD stated: “The votes of the Midwest CEPAC reflected the remaining uncertainties around the benefits of these therapies and the overwhelming certainty that […]